These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15610250)

  • 1. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.
    Jafar TH; Stark PC; Schmid CH; Strandgaard S; Kamper AL; Maschio G; Becker G; Perrone RD; Levey AS;
    Kidney Int; 2005 Jan; 67(1):265-71. PubMed ID: 15610250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
    Jafar TH; Stark PC; Schmid CH; Landa M; Maschio G; Marcantoni C; de Jong PE; de Zeeuw D; Shahinfar S; Ruggenenti P; Remuzzi G; Levey AS;
    Kidney Int; 2001 Sep; 60(3):1131-40. PubMed ID: 11532109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
    Jafar TH; Schmid CH; Landa M; Giatras I; Toto R; Remuzzi G; Maschio G; Brenner BM; Kamper A; Zucchelli P; Becker G; Himmelmann A; Bannister K; Landais P; Shahinfar S; de Jong PE; de Zeeuw D; Lau J; Levey AS
    Ann Intern Med; 2001 Jul; 135(2):73-87. PubMed ID: 11453706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.
    Jafar TH; Stark PC; Schmid CH; Landa M; Maschio G; de Jong PE; de Zeeuw D; Shahinfar S; Toto R; Levey AS;
    Ann Intern Med; 2003 Aug; 139(4):244-52. PubMed ID: 12965979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.
    Kent DM; Jafar TH; Hayward RA; Tighiouart H; Landa M; de Jong P; de Zeeuw D; Remuzzi G; Kamper AL; Levey AS
    J Am Soc Nephrol; 2007 Jun; 18(6):1959-65. PubMed ID: 17475813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.
    Jafar TH; Schmid CH; Stark PC; Toto R; Remuzzi G; Ruggenenti P; Marcantoni C; Becker G; Shahinfar S; De Jong PE; De Zeeuw D; Kamper AL; Strangaard S; Levey AS
    Nephrol Dial Transplant; 2003 Oct; 18(10):2047-53. PubMed ID: 13679479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H; Hayashi K; Saruta T
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
    Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
    Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
    Agarwal R; Siva S; Dunn SR; Sharma K
    Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R
    Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS
    Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.
    Braun C; Kleemann T; Hilgenfeldt U; Riester U; Rohmeiss P; van der Woude FJ
    Kidney Int; 2002 Jun; 61(6):2149-56. PubMed ID: 12028455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
    Coppo R; Peruzzi L; Amore A; Piccoli A; Cochat P; Stone R; Kirschstein M; Linné T
    J Am Soc Nephrol; 2007 Jun; 18(6):1880-8. PubMed ID: 17513327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.